• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Carl Zeiss Meditec, LDT acquisition complete

Article

Dublin, CA-Carl Zeiss Meditec Inc. completed the acquisition of Laser Diagnostic Technologies (LDT), maker of a complementary technology aimed at measuring optic changes that lead to glaucoma diagnosis.

Dublin, CA-Carl Zeiss Meditec Inc. completed the acquisition of Laser Diagnostic Technologies (LDT), maker of a complementary technology aimed at measuring optic changes that lead to glaucoma diagnosis.

San Diego-based LDT, which made the GDx VCC to measure changes to the retinal nerve fiber layer, has projected revenues of $20 million. The deal, announced Oct. 21, gives Carl Zeiss Meditec "a greater breadth of important options for the diagnosis and management of glaucoma," according to Jim Taylor, president and chief executive officer for Carl Zeiss Meditec.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.